摘要
目的 探讨FLT3-ITD突变阳性急性髓系白血病(AML)的临床特征和预后因素,为FLT3-ITD突变阳性AML患者的预后评估提供更多证据.方法 收集98例FLT3-ITD突变阳性AML初诊患者的临床资料,对其临床特征与预后的相关性进行统计学分析.结果 98例FLT3-ITD突变阳性AML患者初诊时中位WBC 58.2 (0.3~ 461.8)×10^9/L,外周血原始细胞绝对计数中位数42.2(0~397.1)×10^9/L.71例细胞遗传学中高危组患者1个疗程完全缓解(CR)率为60.6%,原发耐药率为26.8%.单因素分析结果显示外周血原始细胞绝对计数低是影响患者1个疗程CR的良好预后因素(P=0.009).多因素分析结果显示,1个疗程达CR (HR=0.395,95% CI 0.183~0.850,P=0.001)及第1次CR期行异基因造血干细胞移植(HR=0.180,95%CI 0.043~0.752,P=0.018)是影响患者无复发生存的良好预后因素,1个疗程达CR(HR=0.251,95%CI 0.121~0.523,P<0.001)及外周血原始细胞绝对计数低(HR=0.219,95%CI 0.088~0.545,P=0.003)是影响患者总生存的良好预后因素.结论 外周血原始细胞计数低的FLT3-ITD突变阳性AML患者预后相对良好,1个疗程达CR和第1次CR期行异基因造血干细胞移植是改善FLT3-ITD突变阳性AML患者预后的重要治疗策略.
Objective To investigate the clinical significance and prognosis factors of acute myeloid leukemia (AML) with FLT3 mutation-internal tandem duplication (FLT3-ITD) and provide more evidence for prognosis evaluation in AML with FLT3-ITD.Methods The clinical characteristics and outcomes of 98 AML with FLT3-ITD were analyzed.Results In patients with FLT3-ITD positive AML,the median of WBC and peripheral blood blast at initial diagnosis were 58.2 (0.3-461.8)× 10^9/L and 42.2 (0-397.1) × 10^9/L,respectively.The complete remission (CR) rate after one course induction therapy was 60.6% in 71 patients with intermediate or adverse risk.The primary refractory rate was 26.8% in 71 patients with intermediate or adverse risk.The lower number of peripheral blood blast was a favorable factor to achieve CR after one course induction therapy(P=0.009).CR after one course (HR=0.395,95% CI 0.183-0.85,P=0.001) and allo-transplantation in CR1 (HR=0.180,95% CI 0.043-0.752,P=0.018) favored longer relapse-free survival (RFS).CR after one course (HR=0.25 1,95% CI 0.121-0.523,P〈 0.001) and lower number of peripheral blood blast (HR=0.219,95% CI 0.088-0.545,P=0.003) favored longer overall survival (OS) in AML with FLT3-ITD.Conclusion FLT3-ITD positive AML with lower number of peripheral blood blast has a relative favorable prognosis.CR after one course and allotransplantation in CR1 are important strategy to improve prognosis in AML with FLT3-ITD.
出处
《中华血液学杂志》
CAS
CSCD
北大核心
2016年第12期1017-1021,共5页
Chinese Journal of Hematology
基金
国家自然科学基金重点项目(81430004)
天津市自然科学基金(15JCYBJC25700、15JCYBJC25000)